The average one-year price target for PTC Therapeutics (NasdaqGS:PTCT) has been revised to $80.45 / share. This is an increase of 15.54% from the prior estimate of $69.63 dated November 7, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $50.50 to a high of $123.90 / share. The average price target represents an increase of 6.84% from the latest reported closing price of $75.30 / share.
What is the Fund Sentiment?
There are 648 funds or institutions reporting positions in PTC Therapeutics. This is an increase of 46 owner(s) or 7.64% in the last quarter. Average portfolio weight of all funds dedicated to PTCT is 0.23%, an increase of 32.17%. Total shares owned by institutions increased in the last three months by 5.41% to 94,758K shares. 
The put/call ratio of PTCT is 0.36, indicating a bullish outlook.
What are Other Shareholders Doing?
Rtw Investments holds 7,746K shares representing 9.65% ownership of the company. No change in the last quarter.
Wellington Management Group Llp holds 4,919K shares representing 6.13% ownership of the company. In its prior filing, the firm reported owning 4,694K shares , representing an increase of 4.56%. The firm decreased its portfolio allocation in PTCT by 82.03% over the last quarter.
Armistice Capital holds 4,735K shares representing 5.90% ownership of the company. In its prior filing, the firm reported owning 5,435K shares , representing a decrease of 14.77%. The firm decreased its portfolio allocation in PTCT by 3.86% over the last quarter.
Janus Henderson Group holds 3,774K shares representing 4.70% ownership of the company. In its prior filing, the firm reported owning 3,175K shares , representing an increase of 15.86%. The firm decreased its portfolio allocation in PTCT by 46.36% over the last quarter.
Toronto Dominion Bank holds 3,247K shares representing 4.04% ownership of the company. In its prior filing, the firm reported owning 2,446K shares , representing an increase of 24.66%. The firm decreased its portfolio allocation in PTCT by 42.21% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
